Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 20/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 6/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7391613 | 0.89 | CYP3A4 (0.56) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL27900691 | 0.89 | CYP3A4 (0.56) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL1389204 | 0.89 | CYP3A4 (0.56) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL7181294 | 0.88 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL7527628 | 0.88 | CYP3A4 (0.55) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL10201902 | 0.86 | CYP3A4 (0.49) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL10201898 | 0.86 | CYP3A4 (0.52) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL18715769 | 0.86 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL2736292 | 0.85 | CYP3A4 (0.53) | CYP3A4CYP2D6CYP2C19CYP2C9CYP1A2 | |
| SCHEMBL11919331 | 0.85 | CYP3A4 (0.49) | CYP3A4CYP2D6CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158647-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-05-25 | — | — | US | disclosed |
| EP-3150586-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | Gilead Sciences, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| US-9575080-B2 | — | — | 2017-02-21 | — | — | US | disclosed |
| EP-3112355-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2017-01-04 | — | — | EP | disclosed |
| US-20160303088-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2016-10-20 | — | — | US | disclosed |
| EP-2487165-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-09-14 | — | — | EP | disclosed |
| EP-2487163-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2487162-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-08-17 | — | — | EP | disclosed |
| EP-2487161-B1 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES INC (US) | 2016-08-10 | — | — | EP | disclosed |
| US-5591860-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1997-01-07 | — | — | US | disclosed |
| US-5583232-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-10 | — | — | US | disclosed |
| US-5583233-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS | ABBOTT LABORATORIES (US) | 1996-12-10 | — | — | US | disclosed |
| US-5580984-A | 1-OXA-3-AZA-2-BORINE INTERMEDIATES | ABBOTT LABORATORIES (US) | 1996-12-03 | — | — | US | disclosed |
| US-5565418-A | PREPARING CARBAMATE INTERMEDIATES BY REACTING SUBSTITUTED HYDROXYDIAMINE COMPOUND WITH ONE AMINE PROTECTED WITH ACTIVATED ACYLATING AGENT, DEPROTECTING | ABBOTT LABORATORIES (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0674513-B1 | RETROVIRAL PROTEASE INHIBITING COMPOUNDS | ABBOTT LAB (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5552558-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1996-09-03 | — | — | US | disclosed |
| EP-0727419-A2 | Retroviral protease inhibiting compounds | Abbott Laboratories (US) | 1996-08-21 | — | — | EP | disclosed |
| US-5541206-A | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTION | ABBOTT LABORATORIES (US) | 1996-07-30 | — | — | US | disclosed |
| US-5539122-A | Retroviral protease inhibiting compounds | ABBOTT LABORATORIES (US) | 1996-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160303088-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CYP3A4 415/4885CYP2D6 140/4885CYP2C19 716/4885 |
| US-20170158647-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | CYP3A4 160/4885CYP2D6 105/4885CYP2C19 576/4885 |
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | CYP3A4 415/4885CYP2D6 140/4885CYP2C19 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.